Bio-Techne Corp Files 8-K on Operations and Personnel

TL;DR

Bio-Techne dropped an 8-K detailing Q2 results and exec changes. Check it out.

AI Summary

Bio-Techne Corporation filed an 8-K on February 5, 2025, reporting on events as of January 30, 2025. The filing covers results of operations, financial condition, director and officer changes, and other events. It also includes financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Bio-Techne's financial performance and any significant changes in its leadership or corporate structure.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of operational and personnel information, not indicating any immediate financial distress or significant negative events.

Key Numbers

• 0001558370-25-000639 — Accession Number (Unique identifier for the filing)
• 20250205 — Filing Date (Date the report was filed with the SEC)
• 20250130 — Report Date (Date of the earliest event reported)

Key Players & Entities

• BIO-TECHNE Corporation (company) — Registrant
• Minnesota (location) — State of Incorporation
• 614 McKinley Place NE (location) — Principal Executive Offices Address
• Minneapolis (location) — City of Principal Executive Offices
• 55413 (location) — Zip Code of Principal Executive Offices
• 612-379-8854 (phone_number) — Registrant's Phone Number

FAQ

Key Financial Figures

• $120,000 — to earn total compensation in excess of $120,000 for the current fiscal year. He earned
• $260,000 — nt fiscal year. He earned approximately $260,000 and $295,000 in total compensation duri
• $295,000 — r. He earned approximately $260,000 and $295,000 in total compensation during our 2024 a

Filing Documents

• tech-20250130x8k.htm (8-K) — 43KB
• tech-20250130xex99d1.htm (EX-99.1) — 619KB
• tech-20250130xex99d2.htm (EX-99.2) — 21KB
• tech-20250130xex99d3.htm (EX-99.3) — 9KB
• 0001558370-25-000639.txt ( ) — 853KB
• tech-20250130.xsd (EX-101.SCH) — 3KB
• tech-20250130_lab.xml (EX-101.LAB) — 15KB
• tech-20250130_pre.xml (EX-101.PRE) — 11KB
• tech-20250130x8k_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 5, 2025, describing the results of operations for the quarter ended December 31, 2024, and its financial condition as of December 31, 2024 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 30, 2025, Bio-Techne Corporation (the "Company") appointed Dr. Amy Herr to the Company's Board of Directors as an independent director. Dr. Herr's tenure as a director will begin on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Amy E. Herr, Ph.D., is currently a Chancellor's Professor of Bioengineering at the University of California, Berkeley and the Vice President of Chan Zuckerberg Biohub Network, a group of nonprofit research institutes that focuses on understanding underlying mechanisms of disease and developing new technologies that will lead to actionable diagnostics and effective therapies. Dr. Herr holds a Master of Science degree and a Doctor of Philosophy degree from Stanford University. Dr. Herr was identified, evaluated, and recruited to join the Board as part of the Board's two-year process to replace retiring directors Dr. Randy Steer and Dr. Roeland Nusse. The process relied on external resources such as recruiting firms, commercial partners and external networks to source qualified candidates.

01 Other Events

Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on February 5, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2. A copy of the press release issued by Bio-Techne Corporation on February 4, 2025, announcing Dr. Herr's appointment is attached hereto as Exhibit 99.3.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release, dated February 5, 2025, announcing results of operations 99.2 Press Release, dated February 5, 2025, announcing cash dividend 99.3 Press Release, dated February 4, 2025, announcing appointment of Dr. Herr as director 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: February 5, 2025 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR